IP Library Granted Patent US 11,673,959
Granted Patent B2
US 11,673,959 · App. 16/835,171 · Granted Jun 13, 2023

Coiled coil immunoglobulin fusion proteins and compositions thereof

Inventors: Feng Wang (Carlsbad, CA); Yong Zhang (Temple City, CA); Yan Liu (San Diego, CA); Peter G. Schultz (La Jolla, CA)
Assignee: THE SCRIPPS RESEARCH INSTITUTE
C07K16/2863A61K39/395A61K47/65A61K47/6889C07K14/43522C07K14/47C07K14/505C07K14/535C07K14/5759C07K14/57563C07K14/605C07K14/61C07K14/64C07K14/70503C07K14/811C07K16/1027C07K16/2866C07K16/32A61K2039/505C07K2317/24C07K2317/565C07K2317/76C07K2317/92C07K2318/10C07K2319/00C07K2319/30C07K2319/33C07K2319/50C07K2319/55C07K2319/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,673,959
App. No.
16/835,171
Granted
Jun 13, 2023
Kind
B2
Abstract

Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

Claims (11)

1. An immunoglobulin fusion protein comprising a human or humanized antibody domain and a first extender fusion region positioned within the antibody domain, wherein the first extender fusion region comprises a therapeutic agent positioned between a first extender peptide and a second extender peptide, the first extender peptide comprising (AKLAALK)n (SEQ ID NO: 148) where n is from 1 to 5, and the second extender peptide comprising (ELAALEA)m (SEQ ID NO: 158) where m is from 1 to 5.

2. The immunoglobulin fusion protein of claim 1 , wherein n is from 1 to 3.

3. The immunoglobulin fusion protein of claim 1 , wherein n is 2.

4. The immunoglobulin fusion protein of claim 1 , wherein m is from 1 to 3.

5. The immunoglobulin fusion protein of claim 1 , wherein m is 2.

6. The immunoglobulin fusion protein of claim 1 , wherein the antibody domain comprises a heavy chain and a light chain, and the antibody domain comprises an antibody variable domain, and the first extender fusion region is positioned within the antibody variable domain.

7. The immunoglobulin fusion protein of claim 6 , wherein the first extender fusion region is positioned within a CDR of the antibody variable domain.

8. The immunoglobulin fusion protein of claim 6 , wherein the first extender fusion region is positioned within a CDR3 of the antibody variable domain.

9. The immunoglobulin fusion protein of claim 6 , wherein the first extender fusion region is positioned within the CDR3 of the heavy chain of the antibody variable domain.

10. The immunoglobulin fusion protein of claim 6 , wherein the first extender fusion region is positioned within the CDR3 of the light chain of the antibody variable domain.

11. The immunoglobulin fusion protein of claim 6 , wherein the first extender fusion region replaces a portion of the antibody variable domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2020
From: WANG, FENG; SCHULTZ, PETER G.; ZHANG, YONG; LIU, YAN
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 053924/0817 →
Continuity (6)
Continuation 14903492
Provisional Application 62017713 · Jun 26, 2014
Provisional Application 61925904 · Jan 10, 2014
Provisional Application 61845287 · Jul 11, 2013
Provisional Application 61845280 · Jul 11, 2013
Related Publication 20200270353A1 · Aug 27, 2020